organization · Reporting owner

Johnson & Johnson Innovation - JJDC, Inc.

Disclosed activity across 18 companies

Tapewire entity: 11151
SEC CIK: 0000924020

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aldeyra Therapeutics, Inc.ALDX · Entity 6839	10% owner	May 01, 2014	May 05, 2014
BARRIER THERAPEUTICS INCBTRX · Entity 13927	10% owner	February 15, 2005	February 15, 2005
CRITICAL THERAPEUTICS INCCRTX · Entity 14044	10% owner	June 02, 2004	June 02, 2004
Contineum Therapeutics, Inc.CTNM · Entity 5311	10% owner	April 09, 2024	April 10, 2024
Protagonist Therapeutics, IncPTGX · Entity 3552	10% owner	August 16, 2016	August 18, 2016

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aldeyra Therapeutics, Inc.

Report date May 01, 2014 · Filed May 05, 2014

Jointly reported with JOHNSON & JOHNSON

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectJohnson & Johnson Development Corporation	1,750,292	Last balance in matching sequence After 2014-05-01 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 5 source rows Row 1 · 2014-05-01 · Conversion · Acquired 1,724,478 · Balance 1,724,478 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2014-05-01 · Exercise / conversion · Acquired 36,345 · Balance 1,760,823 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 3 · 2014-05-01 · Tax withholding · Disposed 23,438 · Balance 1,737,385 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 4 · 2014-05-01 · Exercise / conversion · Acquired 36,345 · Balance 1,773,730 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 5 · 2014-05-01 · Tax withholding · Disposed 23,438 · Balance 1,750,292 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Development Corporation	0	Reported balance After 2014-05-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2014-05-01 · Conversion · Disposed 385,800 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
Non-Voting Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Development Corporation	0	Reported balance After 2014-05-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2014-05-01 · Conversion · Disposed 104,396 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Development Corporation	0	Reported balance After 2014-05-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2014-05-01 · Conversion · Disposed 427,591 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
Non-Voting Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Development Corporation	0	Reported balance After 2014-05-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2014-05-01 · Conversion · Disposed 133,827 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
Series B Preferred Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.16 · Expires 2017-12-20	IndirectBy Johnson & Johnson Development Corporation	0	Reported balance After 2014-05-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2014-05-01 · Exercise / conversion · Disposed 36,345 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F3: All outstanding warrants were net exercised for shares of the Issuer's Series B Preferred Stock and subsequently automatically converted into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
Series B Preferred Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.16 · Expires 2018-08-14	IndirectBy Johnson & Johnson Development Corporation	0	Reported balance After 2014-05-01 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2014-05-01 · Exercise / conversion · Disposed 36,345 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F3: All outstanding warrants were net exercised for shares of the Issuer's Series B Preferred Stock and subsequently automatically converted into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.

F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis.

F3: All outstanding warrants were net exercised for shares of the Issuer's Series B Preferred Stock and subsequently automatically converted into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis.

BARRIER THERAPEUTICS INC

Report date February 15, 2005 · Filed February 15, 2005

Jointly reported with JOHNSON & JOHNSON, Johnson & Johnson Consumer Companies, Inc., Janssen Pharmaceutica Products, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy three subsidiaries	3,753,749	Reported balance After 2005-02-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2005-02-15 · Sale · Disposed 694,327 · Balance 3,753,749 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following wholly-owned subsidiaries of the Reporting Person: Johnson & Johnson Development Corporation ("JJDC") (selling 25,000 shares of Common Stock); Johnson & Johnson Consumer Companies, Inc. ("JJCC") (selling 160,638 shares of Common Stock); and Janssen Pharmaceutica Products, L.P. ("JPP") (selling 508,689 shares of Common Stock). Following the reported sale, JJDC will own 256,410 shares of Common Stock; JJCC will own 856,028 shares of Common Stock; and JPP will own 2,641,311 shares of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following wholly-owned subsidiaries of the Reporting Person: Johnson & Johnson Development Corporation ("JJDC") (selling 25,000 shares of Common Stock); Johnson & Johnson Consumer Companies, Inc. ("JJCC") (selling 160,638 shares of Common Stock); and Janssen Pharmaceutica Products, L.P. ("JPP") (selling 508,689 shares of Common Stock). Following the reported sale, JJDC will own 256,410 shares of Common Stock; JJCC will own 856,028 shares of Common Stock; and JPP will own 2,641,311 shares of Common Stock.

CRITICAL THERAPEUTICS INC

Report date June 02, 2004 · Filed June 02, 2004

Jointly reported with JOHNSON & JOHNSON

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Johnson & Johnson Development Corporation	2,104,704	Last balance in matching sequence After 2004-06-02 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2004-06-02 · Conversion · Acquired 1,961,904 · Balance 1,961,904 F1: All of the preferred stock was automatically converted on a 1-for-3.75 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. Row 2 · 2004-06-02 · Purchase · Acquired 142,800 · Balance 2,104,704 F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Development Corporation	0	Reported balance After 2004-06-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2004-06-02 · Conversion · Disposed 2,000,000 · Balance 0 F1: All of the preferred stock was automatically converted on a 1-for-3.75 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Development Corporation	0	Reported balance After 2004-06-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2004-06-02 · Conversion · Disposed 5,357,143 · Balance 0 F1: All of the preferred stock was automatically converted on a 1-for-3.75 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: All of the preferred stock was automatically converted on a 1-for-3.75 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering.

F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person.

Contineum Therapeutics, Inc.

Report date April 09, 2024 · Filed April 10, 2024

Jointly reported with JOHNSON & JOHNSON

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,979,173	Reported balance Holding disclosure · report date 2024-04-09 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,979,173 F1: The securities reported as indirectly beneficially owned by Johnson & Johnson are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported as indirectly beneficially owned by Johnson & Johnson are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson.

Protagonist Therapeutics, Inc

Report date August 16, 2016 · Filed August 18, 2016

Jointly reported with JOHNSON & JOHNSON

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	2,449,183	Last balance in matching sequence After 2016-08-16 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2016-08-16 · Conversion · Acquired 965,517 · Balance 965,517 F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2016-08-16 · Conversion · Acquired 900,333 · Balance 1,865,850 F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Row 3 · 2016-08-16 · Purchase · Acquired 583,333 · Balance 2,449,183 F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	0	Reported balance After 2016-08-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-08-16 · Conversion · Disposed 14,000,000 · Balance 0 F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	0	Reported balance After 2016-08-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-08-16 · Conversion · Disposed 13,054,830 · Balance 0 F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date.

F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration.

F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

Past disclosures · reporting ended (13)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACHILLION PHARMACEUTICALS INC

Report date November 20, 2017 · Filed November 22, 2017

Jointly reported with JOHNSON & JOHNSON

Section 16 reporting ended · disclosed 2017-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	0	Reported balance After 2017-11-20 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-11-20 · Sale · Disposed 18,367,346 · Balance 0 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

Filing footnotes · ownership attribution and instrument terms

CVRx, Inc.

Report date November 25, 2025 · Filed January 08, 2026 · Amendment

Jointly reported with JOHNSON & JOHNSON

Section 16 reporting ended · disclosed 2024-02-02. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	4,024,861	Last balance in matching sequence After 2025-11-26 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2025-11-25 · Sale · Disposed 16,000 · Balance 4,031,198 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. Row 2 · 2025-11-26 · Sale · Disposed 6,337 · Balance 4,024,861 F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Fusion Pharmaceuticals Inc.

Report date June 30, 2020 · Filed July 02, 2020

Jointly reported with JOHNSON & JOHNSON

Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	3,670,516	Last balance in matching sequence After 2020-06-30 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2020-06-30 · Conversion · Acquired 2,945,516 · Balance 2,945,516 F1: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2020-06-30 · Purchase · Acquired 725,000 · Balance 3,670,516 F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Class A Preferred SharesSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	0	Reported balance After 2020-06-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-06-30 · Conversion · Disposed 10,666,667 · Balance 0 F1: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Class B Preferred SharesSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	0	Reported balance After 2020-06-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-06-30 · Conversion · Disposed 5,059,460 · Balance 0 F1: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Warrants to purchase Class B Preferred SharesSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	0	Reported balance After 2020-06-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-06-30 · Conversion · Disposed 475,802 · Balance 0 F3: Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares converted to Warrants to purchase Common Shares at an exercise price of $8.10 per share. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Warrants to purchase Common SharesSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	89,118	Reported balance After 2020-06-30 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-06-30 · Conversion · Acquired 89,118 · Balance 89,118 F3: Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares converted to Warrants to purchase Common Shares at an exercise price of $8.10 per share. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date.

F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

F3: Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares converted to Warrants to purchase Common Shares at an exercise price of $8.10 per share.

GENOCEA BIOSCIENCES, INC.

Report date February 10, 2014 · Filed February 11, 2014

Jointly reported with JOHNSON & JOHNSON

Section 16 reporting ended · disclosed 2014-02-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectJohnson & Johnson Development Corporation	1,388,645	Reported balance After 2014-02-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2014-02-10 · Conversion · Acquired 1,388,645 · Balance 1,388,645 F2: Upon closing of the Issuer's initial public offering (the "IPO") the Series B Preferred Stock, including all accrued and unpaid dividends, converted automatically into Common Stock on a 1-for-11.9 basis without payment of further consideration. The Series B Preferred Stock had an accruing cumulative dividend that accrued at a rate of 8% per year from the Series B Preferred Stock issuance date. 208,862 shares were issued to Johnson & Johnson Development Corporation in payment of accrued and unpaid dividends. Upon closing of the IPO the Series C Preferred Stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for any series of preferred stock. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Development Corporation	0	Reported balance After 2014-02-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2014-02-10 · Conversion · Disposed 827,917 · Balance 0 F2: Upon closing of the Issuer's initial public offering (the "IPO") the Series B Preferred Stock, including all accrued and unpaid dividends, converted automatically into Common Stock on a 1-for-11.9 basis without payment of further consideration. The Series B Preferred Stock had an accruing cumulative dividend that accrued at a rate of 8% per year from the Series B Preferred Stock issuance date. 208,862 shares were issued to Johnson & Johnson Development Corporation in payment of accrued and unpaid dividends. Upon closing of the IPO the Series C Preferred Stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for any series of preferred stock. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Development Corporation	Not disclosed	Reported balance After 2014-02-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2014-02-10 · Conversion · Disposed 351,866 · Balance Not disclosed F2: Upon closing of the Issuer's initial public offering (the "IPO") the Series B Preferred Stock, including all accrued and unpaid dividends, converted automatically into Common Stock on a 1-for-11.9 basis without payment of further consideration. The Series B Preferred Stock had an accruing cumulative dividend that accrued at a rate of 8% per year from the Series B Preferred Stock issuance date. 208,862 shares were issued to Johnson & Johnson Development Corporation in payment of accrued and unpaid dividends. Upon closing of the IPO the Series C Preferred Stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for any series of preferred stock. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F2: Upon closing of the Issuer's initial public offering (the "IPO") the Series B Preferred Stock, including all accrued and unpaid dividends, converted automatically into Common Stock on a 1-for-11.9 basis without payment of further consideration. The Series B Preferred Stock had an accruing cumulative dividend that accrued at a rate of 8% per year from the Series B Preferred Stock issuance date. 208,862 shares were issued to Johnson & Johnson Development Corporation in payment of accrued and unpaid dividends. Upon closing of the IPO the Series C Preferred Stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for any series of preferred stock.

IMMUNICON CORP

Report date June 10, 2004 · Filed June 14, 2004

Jointly reported with JOHNSON & JOHNSON

Section 16 reporting ended · disclosed 2004-06-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Johnson & Johnson Development Corporation	1,771,571	Reported balance After 2004-06-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2004-06-10 · Other · Acquired 2,667 · Balance 1,771,571 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation ("JJDC"), a wholly-owned subsidiary of the Reporting Person.
Common Stock Warrant PurchaseSEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2004-07-14	IndirectBy Johnson & Johnson Development Corporation	0	Reported balance After 2004-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2004-06-10 · Other · Disposed 2,667 · Balance 0 F2: Pursuant to the terms of the warrant, the Reporting Persons had 90 days from the date JJDC's director designee resigned from the Issuer's Board of Directors to exercise the warrant as no other director designee was selected by JJDC. JJDC's director designee resigned from the board on April 15, 2004, triggering the 90 day period. F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation ("JJDC"), a wholly-owned subsidiary of the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation ("JJDC"), a wholly-owned subsidiary of the Reporting Person.

F2: Pursuant to the terms of the warrant, the Reporting Persons had 90 days from the date JJDC's director designee resigned from the Issuer's Board of Directors to exercise the warrant as no other director designee was selected by JJDC. JJDC's director designee resigned from the board on April 15, 2004, triggering the 90 day period.

Inspire Medical Systems, Inc.

Report date May 07, 2018 · Filed May 07, 2018

Jointly reported with JOHNSON & JOHNSON

Section 16 reporting ended · disclosed 2018-05-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	235,251	Last balance in matching sequence After 2018-05-07 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2018-05-07 · Conversion · Acquired 197,863 · Balance 197,863 F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F2: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate. F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2018-05-07 · Conversion · Acquired 37,388 · Balance 235,251 F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F3: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate. F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Series E Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	0	Reported balance After 2018-05-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-05-07 · Conversion · Disposed 1,145,038 · Balance 0 F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F2: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate. F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Series F Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	0	Reported balance After 2018-05-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-05-07 · Conversion · Disposed 248,631 · Balance 0 F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F3: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate. F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering.

F2: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate.

F3: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate.

F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

MeiraGTx Holdings plc

Report date September 15, 2023 · Filed September 18, 2023

Section 16 reporting ended · disclosed 2023-09-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	6,641,064	Reported balance Holding disclosure · report date 2023-09-15 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 6,641,064 F1: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 4 will be filed to disclose Old JJDC's disposition of the securities reported herein.

Filing footnotes · ownership attribution and instrument terms

F1: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 4 will be filed to disclose Old JJDC's disposition of the securities reported herein.

Minerva Neurosciences, Inc.

Report date August 29, 2017 · Filed September 14, 2017

Jointly reported with JOHNSON & JOHNSON

Section 16 reporting ended · disclosed 2017-09-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	0	Reported balance After 2017-08-29 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-08-29 · Other · Disposed 3,892,256 · Balance 0 F1: The shares were repurchased by the Issuer at their par value in connection with the amendment of a co-development and license agreement between the Issuer and an affiliate of Johnson & Johnson Innovation - JJDC, Inc. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were repurchased by the Issuer at their par value in connection with the amendment of a co-development and license agreement between the Issuer and an affiliate of Johnson & Johnson Innovation - JJDC, Inc.

F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the Reporting Person.

NEVRO CORP

Report date December 31, 2015 · Filed February 12, 2016

Jointly reported with JOHNSON & JOHNSON

Section 16 reporting ended · disclosed 2016-02-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	2,066,740	Reported balance After 2015-06-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2015-06-08 · Sale · Disposed 1,010,265 · Balance 2,066,740 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owed subsidiary of the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owed subsidiary of the Reporting Person.

Neurogene Inc.

Report date August 10, 2015 · Filed August 12, 2015

Jointly reported with JOHNSON & JOHNSON

Section 16 reporting ended · disclosed 2015-08-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectJohnson & Johnson Innovation - JJDC, Inc.	100,000	Last balance in matching sequence After 2015-08-11 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2015-08-10 · Sale · Disposed 231,455 · Balance 1,383,366 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Johnson & Johnson Development Corporation changed its name to Johnson & Johnson Innovation - JJDC, Inc. on November 3, 2014. Row 2 · 2015-08-11 · Sale · Disposed 1,283,366 · Balance 100,000 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.55 to $30.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Johnson & Johnson Development Corporation changed its name to Johnson & Johnson Innovation - JJDC, Inc. on November 3, 2014.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Johnson & Johnson Development Corporation changed its name to Johnson & Johnson Innovation - JJDC, Inc. on November 3, 2014.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.55 to $30.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Provention Bio, Inc.

Report date July 19, 2018 · Filed July 20, 2018

Jointly reported with JOHNSON & JOHNSON

Section 16 reporting ended · disclosed 2018-07-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	2,400,000	Reported balance After 2018-07-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-07-19 · Conversion · Acquired 2,400,000 · Balance 2,400,000 F1: The Series A Preferred Stock had no expiration date and was automatically converted into shares of Common Stock on a 1-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Innovation - JJDC, Inc.	0	Reported balance After 2018-07-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-07-19 · Conversion · Disposed 2,400,000 · Balance 0 F1: The Series A Preferred Stock had no expiration date and was automatically converted into shares of Common Stock on a 1-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Preferred Stock had no expiration date and was automatically converted into shares of Common Stock on a 1-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering.

TENGION INC

Report date April 14, 2010 · Filed April 14, 2010

Jointly reported with JOHNSON & JOHNSON

Section 16 reporting ended · disclosed 2010-04-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectJohnson & Johnson Development Corporation	1,194,654	Last balance in matching sequence After 2010-04-14 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2010-04-14 · Conversion · Acquired 755,053 · Balance 794,654 F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2010-04-14 · Purchase · Acquired 400,000 · Balance 1,194,654 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Development Corporation	0	Reported balance After 2010-04-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2010-04-14 · Conversion · Disposed 4,961,653 · Balance 0 F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Development Corporation	0	Reported balance After 2010-04-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2010-04-14 · Conversion · Disposed 2,162,818 · Balance 0 F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectBy Johnson & Johnson Development Corporation	0	Reported balance After 2010-04-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2010-04-14 · Conversion · Disposed 3,823,817 · Balance 0 F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration.

UNIVERSAL BIOSENSORS INC

Report date December 31, 2011 · Filed January 24, 2012

Jointly reported with JOHNSON & JOHNSON

Section 16 reporting ended · disclosed 2012-01-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Johnson & Johnson Development Corporation	15,749,937	Last balance in matching sequence After 2011-09-08 transaction · row 17 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 17 source rows Row 1 · 2011-03-08 · Sale · Disposed 25,000 · Balance 17,406,617 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 2 · 2011-03-09 · Sale · Disposed 25,000 · Balance 17,381,617 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 3 · 2011-03-10 · Sale · Disposed 25,000 · Balance 17,356,617 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 4 · 2011-03-21 · Sale · Disposed 4,900 · Balance 17,351,717 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 5 · 2011-03-29 · Sale · Disposed 32 · Balance 17,351,685 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 6 · 2011-03-30 · Sale · Disposed 155 · Balance 17,351,530 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 7 · 2011-04-14 · Sale · Disposed 10,000 · Balance 17,341,530 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 8 · 2011-04-15 · Sale · Disposed 7,500 · Balance 17,334,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 9 · 2011-04-18 · Sale · Disposed 8,000 · Balance 17,326,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 10 · 2011-04-20 · Sale · Disposed 10,000 · Balance 17,316,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 11 · 2011-04-21 · Sale · Disposed 35,000 · Balance 17,281,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 12 · 2011-04-27 · Sale · Disposed 10,000 · Balance 17,271,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 13 · 2011-04-28 · Sale · Disposed 10,000 · Balance 17,261,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 14 · 2011-04-29 · Sale · Disposed 10,000 · Balance 17,251,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 15 · 2011-07-28 · Sale · Disposed 341 · Balance 17,250,689 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 16 · 2011-08-01 · Sale · Disposed 752 · Balance 17,249,937 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 17 · 2011-09-08 · Sale · Disposed 1,500,000 · Balance 15,749,937 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 26, 2025 Filed Dec 1, 2025 21:07 UTC	CVRx, Inc. CVRX · Entity 6920	SaleCommon Stock	6,337	$10.03	$63,560.11	Disclosure SEC source: 0001193125-25-303876 · ownership.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,040,861 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
November 26, 2025 Filed Jan 8, 2026 21:05 UTC Amendment	CVRx, Inc. CVRX · Entity 6920	SaleCommon Stock	6,337	$10.03	$63,560.11	Disclosure SEC source: 0001193125-26-007679 · ownership.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,024,861 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
November 25, 2025 Filed Jan 8, 2026 21:05 UTC Amendment	CVRx, Inc. CVRX · Entity 6920	SaleCommon Stock	16,000	$10.03	$160,480.00	Disclosure SEC source: 0001193125-26-007679 · ownership.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,031,198 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
November 24, 2025 Filed Nov 25, 2025 17:54 UTC	CVRx, Inc. CVRX · Entity 6920	SaleCommon Stock	2,200	$10.06	$22,132.00	Disclosure SEC source: 0001193125-25-296047 · ownership.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,047,198 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.10. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
November 21, 2025 Filed Nov 25, 2025 17:54 UTC	CVRx, Inc. CVRX · Entity 6920	SaleCommon Stock	500	$10.00	$5,000.00	Disclosure SEC source: 0001193125-25-296047 · ownership.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,049,398 F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
November 12, 2025 Filed Nov 14, 2025 20:07 UTC	CVRx, Inc. CVRX · Entity 6920	SaleCommon Stock	1,000	$10.00	$10,000.00	Disclosure SEC source: 0001193125-25-282669 · ownership.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,049,898 F1 · price: The price reported in Column 4 is a weighted average price. 29 shares were sold at $10.04 and 971 shares were sold at $10.00. F2 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
November 07, 2025 Filed Nov 10, 2025 20:28 UTC	CVRx, Inc. CVRX · Entity 6920	SaleCommon Stock	200	$10.00	$2,000.00	Disclosure SEC source: 0001193125-25-274067 · ownership.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,050,898 F2 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
November 06, 2025 Filed Nov 10, 2025 20:28 UTC	CVRx, Inc. CVRX · Entity 6920	SaleCommon Stock	52,332	$10.21	$534,309.72	Disclosure SEC source: 0001193125-25-274067 · ownership.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,051,098 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.49. The Reporting Persons undertake to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	79	$0.00 Strike: $5.14	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 33 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 79 shares Expires 2031-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F9 · balance_after: 1,185 options previously reported as issued and held by JJDC were previously canceled by the Issuer for no value. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	252	$0.00 Strike: $3.96	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 32 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 252 shares Expires 2029-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F8 · balance_after: 506 options previously reported as issued and held by JJDC were previously canceled by the Issuer for no value. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	142	$0.00 Strike: $1.19	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 31 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc Disclosed balance after: 0 Underlying: Common Stock · 142 shares Expires 2028-11-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	442	$0.00 Strike: $1.19	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 30 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 442 shares Expires 2028-11-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F7 · balance_after: 316 options previously reported as issued and held by JJDC were previously canceled by the Issuer for no value. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	300	$0.00 Strike: $0.24	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 29 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	584	$0.00 Strike: $0.24	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 28 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 584 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F6 · balance_after: 174 options previously reported as issued and held by JJDC were previously canceled by the Issuer for no value. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	489	$0.00 Strike: $0.24	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 27 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 489 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	758	$0.00 Strike: $0.24	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 26 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 758 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	85	$0.00 Strike: $0.24	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 25 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 85 shares Expires 2025-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	23	$0.00 Strike: $0.24	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 24 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 23 shares Expires 2025-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	71	$0.00 Strike: $0.24	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 23 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 71 shares Expires 2025-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	118	$0.00 Strike: $0.24	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 22 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc Disclosed balance after: 0 Underlying: Common Stock · 118 shares Expires 2025-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	165	$0.00 Strike: $0.24	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 21 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 165 shares Expires 2025-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	189	$0.00 Strike: $0.24	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 20 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 189 shares Expires 2025-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionStock Option (Right to Buy) · Derivative	158	$0.00 Strike: $0.24	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 19 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc Disclosed balance after: 0 Underlying: Common Stock · 158 shares Expires 2024-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	79	$5.14	$406.14	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 17 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,103,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	252	$3.96	$996.66	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 16 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,103,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	142	$1.19	$168.41	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 15 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,103,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	442	$1.19	$524.21	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 14 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,102,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	300	$0.24	$71.10	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 13 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,102,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	584	$0.24	$138.41	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 12 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,102,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	489	$0.24	$115.89	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 11 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,101,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	758	$0.24	$179.65	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 10 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,101,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	85	$0.24	$20.15	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 9 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,100,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	23	$0.24	$5.45	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 8 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,100,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	71	$0.24	$16.83	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 7 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,100,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	118	$0.24	$27.97	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 6 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,100,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	165	$0.24	$39.11	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 5 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,100,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	189	$0.24	$44.79	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 4 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,099,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 29, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	Exercise / conversionCommon Stock	158	$0.24	$37.45	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 3 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,099,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 16, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	OtherWarrant to Purchase Common Stock · Derivative	607,225	$0.00 Strike: $0.16	$0.00	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · derivative · entry 18 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 607,225 shares Expires not disclosed F3 · derivative.exercise_date: The Warrant became exercisable for Common Stock upon the closing of the Issuer's initial public offering and was to expire on the earlier of (i) an acquisition or asset transfer involving the Issuer or (ii) 180 days after receipt of the data from the post-market stage of the Issuer's BeAT-HF pivotal trial. F3 · derivative.expiration_date: The Warrant became exercisable for Common Stock upon the closing of the Issuer's initial public offering and was to expire on the earlier of (i) an acquisition or asset transfer involving the Issuer or (ii) 180 days after receipt of the data from the post-market stage of the Issuer's BeAT-HF pivotal trial. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. F4 · ownership.nature: The Warrant was transferred to JJDC from Biosense Webster, Inc., also a wholly-owned subsidiary of Johnson & Johnson, on February 14, 2024. Read SEC document
February 16, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	SaleCommon Stock	3,725	$25.81	$96,142.25	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,099,575 F2 · kind: On February 16, 2024, JJDC exercised the Warrant to purchase 607,725 shares of Common Stock and paid the exercise price (adjusted per the net exercise terms of the Warrant) on a cashless basis, resulting in the withholding of 3,725 of the Warrant shares to pay the exercise price and issuance to JJDC of the remaining 604,000 shares. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
February 16, 2024 Filed Mar 6, 2024 20:42 UTC	CVRx, Inc. CVRX · Entity 6920	OtherCommon Stock	607,725	$0.16	$96,020.55	Disclosure SEC source: 0000950170-24-027095 · ownership.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 4,103,300 F1 · ownership.nature: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a wholly-owned subsidiary of Johnson & Johnson. Read SEC document
September 15, 2023 Filed Sep 18, 2023 13:25 UTC	CVRx, Inc. CVRX · Entity 6920	OtherCommon Stock	3,495,575	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-019200 · doc4.xml · nonDerivative · entry 1 Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · price: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · balance_after: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · ownership.direct: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. Read SEC document
September 15, 2023 Filed Sep 18, 2023 13:36 UTC	MeiraGTx Holdings plc MGTX · Entity 4734	OtherOrdinary Shares	6,641,064	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-019202 · doc4.xml · nonDerivative · entry 1 Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · price: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · balance_after: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · ownership.direct: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. Read SEC document
September 15, 2023 Filed Feb 2, 2024 22:47 UTC Amendment	CVRx, Inc. CVRX · Entity 6920	OtherStock Option (Right to Buy) · Derivative	1,264	Not disclosed Strike: $5.14	Not disclosed	Disclosure SEC source: 0000950170-24-010710 · ownership.xml · derivative · entry 16 Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,264 shares Expires 2031-01-04 F1 · security: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · security: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · kind: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · kind: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · price: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · price: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F5 · derivative.exercise_date: Vests as to 1/48th of the shares each month commencing January 11, 2021. F1 · ownership.direct: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · ownership.direct: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. Read SEC document
September 15, 2023 Filed Feb 2, 2024 22:47 UTC Amendment	CVRx, Inc. CVRX · Entity 6920	OtherStock Option (Right to Buy) · Derivative	758	Not disclosed Strike: $3.96	Not disclosed	Disclosure SEC source: 0000950170-24-010710 · ownership.xml · derivative · entry 15 Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 758 shares Expires 2029-12-05 F1 · security: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · security: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · kind: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · kind: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · price: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · price: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F4 · derivative.exercise_date: Vests as to 1/48th of the shares each month commencing January 6, 2020. F1 · ownership.direct: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · ownership.direct: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. Read SEC document
September 15, 2023 Filed Feb 2, 2024 22:47 UTC Amendment	CVRx, Inc. CVRX · Entity 6920	OtherStock Option (Right to Buy) · Derivative	142	Not disclosed Strike: $1.19	Not disclosed	Disclosure SEC source: 0000950170-24-010710 · ownership.xml · derivative · entry 14 Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 142 shares Expires 2028-11-28 F1 · security: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · security: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · kind: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · kind: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · price: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · price: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F3 · derivative.exercise_date: Fully vested. F1 · ownership.direct: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · ownership.direct: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. Read SEC document
September 15, 2023 Filed Feb 2, 2024 22:47 UTC Amendment	CVRx, Inc. CVRX · Entity 6920	OtherStock Option (Right to Buy) · Derivative	758	Not disclosed Strike: $1.19	Not disclosed	Disclosure SEC source: 0000950170-24-010710 · ownership.xml · derivative · entry 13 Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 758 shares Expires 2028-11-28 F1 · security: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · security: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · kind: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · kind: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · price: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · price: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F3 · derivative.exercise_date: Fully vested. F1 · ownership.direct: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · ownership.direct: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. Read SEC document
September 15, 2023 Filed Feb 2, 2024 22:47 UTC Amendment	CVRx, Inc. CVRX · Entity 6920	OtherStock Option (Right to Buy) · Derivative	300	Not disclosed Strike: $0.24	Not disclosed	Disclosure SEC source: 0000950170-24-010710 · ownership.xml · derivative · entry 12 Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires 2028-02-15 F1 · security: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · security: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · kind: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · kind: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · price: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · price: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F3 · derivative.exercise_date: Fully vested. F1 · ownership.direct: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · ownership.direct: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. Read SEC document
September 15, 2023 Filed Feb 2, 2024 22:47 UTC Amendment	CVRx, Inc. CVRX · Entity 6920	OtherStock Option (Right to Buy) · Derivative	758	Not disclosed Strike: $0.24	Not disclosed	Disclosure SEC source: 0000950170-24-010710 · ownership.xml · derivative · entry 11 Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 758 shares Expires 2028-02-15 F1 · security: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · security: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · kind: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · kind: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · price: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · price: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F3 · derivative.exercise_date: Fully vested. F1 · ownership.direct: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · ownership.direct: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. Read SEC document
September 15, 2023 Filed Feb 2, 2024 22:47 UTC Amendment	CVRx, Inc. CVRX · Entity 6920	OtherStock Option (Right to Buy) · Derivative	489	Not disclosed Strike: $0.24	Not disclosed	Disclosure SEC source: 0000950170-24-010710 · ownership.xml · derivative · entry 10 Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 489 shares Expires 2027-02-01 F1 · security: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · security: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · kind: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · kind: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F1 · price: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · price: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. F3 · derivative.exercise_date: Fully vested. F1 · ownership.direct: This Form 4 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 4 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, F2 · ownership.direct: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 3 Amendment will be filed to disclose New JJDC's beneficial ownership of the securities reported herein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.